Lilly (LLY.US) recommends Elpida peptide as a weight loss drug by the UK regulatory agency.

25/12/2024

GMT Eight

The UK's drug cost-effectiveness watchdog, the National Institute for Health and Care Excellence (NICE), has formally recommended Eli Lilly and Company's GLP-1 drug Tirzepatide as a weight loss medication. The drug is sold under the names Zepbound for weight loss and Moujaro for treating type 2 diabetes. Due to anticipated high demand, NICE had earlier stated in December that Tirzepatide would be rolled out over a three-year period, with the "highest clinical need" patients being given priority for the drug.

CICC 2025 Tourism Hotel and Catering Outlook: Focus on Industry "Infrastructure" Expectation of Recovery in Quantity and Price

CITIC Securities: First initiation of BYD ELECTRONIC(00285) with a "buy" rating. Consumer electronics business revenue in the first half of the year increased significantly year-on-year.

Contact: contact@gmteight.com

Lilly (LLY.US) recommends Elpida peptide as a weight loss drug by the UK regulatory agency.

RECOMMEND

Ningbo Zhongbai (600857.SH) received a court's enforcement ruling.

Suzhou Gyz Electronic Technology (688260.SH) has granted 2 million restricted shares at a price of 13.34 yuan per share.

Huajin Securities: December saw a record number of game licenses issued, with high-quality content and strong IP driving growth.